← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
CGTBiologicstaleNanjing IASO Biotechnology Co.,…Phase 2

Eque-cel (Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection, Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel))

Relapsed/Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 9상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

Lasofoxifene (Lasofoxifene)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 9상태 RECRUITING
CGTBiologicstaleTianjin Medical University Seco…Preclinical

Oncolytic Adenovirus H101 (Oncolytic Adenovirus H101)

Malignant Pleural Mesothelioma, Advanced · Malignant Pleural Mesothelioma, Advanced

#MalignantPleuralMesotheliomaAdva#CGT#Preclinical#세포유전치료#CAR-T+4
임상시험 9상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 3

R-DXd (R-DXd)

Solid Cancer · Solid Cancer

#SolidCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

R-DXd (Raludotatug Deruxtecan, Raludotatug Deruxtecan (R-DXd))

Gastrointestinal Cancer · Gastrointestinal Cancer

#GastrointestinalCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 RECRUITING
CGTAAVBiologicNovartis PharmaceuticalsPhase 2

Rapcabtagene autoleucel (Rapcabtagene autoleucel)

ANCA Associated Vasculitis (AAV) · ANCA Associated Vasculitis (AAV)

#ANCAAssociatedVasculitisAAV#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 9상태 RECRUITING
CGTBiologicstalePersonGen BioTherapeutics (Suzh…Phase 2

TCR-like CAR-T (TCR-like CAR-T)

Safety and Efficacy of TCR-like CAR-T · Safety and Efficacy of TCR-like CAR-T

#SafetyandEfficacyofTCR-likeCAR-T#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 9상태 RECRUITING
CGTBiologicstaleKitePhase 2

Tecartus (Tecartus)

Acute Lymphoblastic Leukemia; Large B-cell Lymphoma · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 86%임상시험 9상태 RECRUITING
AntibodystaleXencor, Inc.Phase 2

XmAb20717 (XmAb20717)

Biliary Tract Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
임상시험 9상태 RECRUITING
ADCBiologicstaleRochePhase 2

Zanubrutinib, Polatuzumab Vedotin, Rituximab (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 ACTIVE
ADCBiologicstaleRochePhase 2

Zanubrutinib, Polatuzumab vedotin and Rituximab (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 ACTIVE
ADCBiologicstaleCelldex TherapeuticsPreclinical

glembatumumab vedotin (glembatumumab vedotin)

Metastatic gpNMB Expressing Triple Negative Breast Cancer · Melanoma

#Melanoma#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 21%임상시험 9상태 ACTIVE
AntibodystaleMacroGenicsPhase 1

lorigerlimab (lorigerlimab)

Advanced Solid Tumor; Castration-Resistant Prostatic Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 9상태 ACTIVE
ADCBiologicstaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, 6 cycle RC48 and JS001)

Urology · Urology

#Urology#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 8상태 RECRUITING
ADCBiologicstaleAbbViePhase 2

ABT-414 (ABT-414)

Malignant Glioma; Glioblastoma Multiforme · Malignant Glioma

#MalignantGlioma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 14.3%임상시험 8상태 ACTIVE
CGTBiologicStephan Grupp MD PhDPhase 1

CART123 (Anti-CD123 LV redirected T cells, Anti-CD123 LV redirected T cells (CART123))

Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia (AML)

#AcuteMyeloidLeukemiaAML#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 8상태 RECRUITING
ADCBiologicstalePfizerPreclinical

Antibody Drug Conjugate Chemotherapeutic (Antibody Drug Conjugate Chemotherapeutic)

CD33 Positive Acute Myelogenous Leukemia · CD33

#CD33#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 51%임상시험 8상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab and Talazoparib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 0%임상시험 8상태 RECRUITING
CGTBiologicHebei Senlang Biotechnology Inc…Phase 1

Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells (Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells)

19 and 22+ B Cell Hematologic Tumors; 19 and 20+ B Cell Hematologic Tumors · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 8상태 RECRUITING
ADCBiologicstaleBayerPhase 1

BAY94-9343 (BAY94-9343)

Neoplasms · Oncology

#Oncology#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 7.2%임상시험 8상태 ACTIVE

48 / 209 페이지

← 이전다음 →